Shanghai Boquan Biotechnology
At a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 16.4/100
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Mar 2023 | $14M | $55M | Sangel Capital · Acer Best · Cowin Venture · Shanghai Biomedicine Fund | ↗ |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Boquan Biotechnology in its local ecosystem
The Shanghai Boquan Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Sangel Capital- ABAcer Best
Cowin Venture- SFShanghai Biomedicine Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Boquan Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Boquan Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.